The State of America's Direct Support Workforce Crisis 2024

New report sheds light on persistent problems facing community providers due to ongoing recruitment and retention challenges
Browse the Data
ANCOR News - 10.26.21

FDA and CDC Approve Moderna and Johnson & Johnson Boosters, As Well As Mix-and-Match Approach to Boosters

Share this page

On Wednesday, the Food and Drug Administration (FDA) announced it was amending its emergency use authorization for COVID-19 vaccines and approved the use of Moderna and Johnson & Johnson COVID-19 boosters, as well as approving a mix-and-match approach to boosters, meaning anyone who is eligible to receive a booster can get a different brand than their original vaccination.

FDA authorized a half-dose of the Moderna COVID-19 vaccine as a booster for certain populations after six months from their last vaccine and authorized the Johnson & Johnson’s booster for all individuals, regardless of age or risk status, at least two months following their initial vaccination.

Moderna and Johnson & Johnson now join Pfizer as FDA-approved COVID-19 boosters. However, eligibility for each booster differs:

Pfizer & Moderna: A single booster dose of the Pfizer-BioNTech or Moderna COVID-19 vaccines may be administered at least six months after completion of the primary series to individuals:

  • 65 years of age and older.
  • 18-64 years of age at high risk of severe COVID-19.
  • 18-64 years of age with frequent institutional or occupational exposure.

Johnson & Johnson: A single booster dose of the Johnson & Johnson COVID-19 Vaccine may be administered at least two months after completion of the single-dose primary regimen to individuals 18 years of age and older.

Mix-and-match: The use of each of the available COVID-19 vaccines as a heterologous booster dose is authorized for any eligible individual following completion of primary vaccination with a different available COVID-19 vaccine.

The day after the FDA’s approval, the Centers for Disease Control and Prevention (CDC) advisory panel met to vote on the use of COVID-19 boosters and echoed the recommendations made by the FDA. The CDC panel unanimously recommended the half-dose Moderna booster for those 65 and up, those who live in long-term care settings, those who have underlying medical conditions, and those who work or live in high-risk settings. The panel also recommended the use of Johnson & Johnson boosters and granted approval for a mix-and-match approach; however, it directed the CDC to provide further guidance to consumers and clinicians about mix-and-match boosters. CDC Director Rochelle Walensky later endorsed the panel’s recommendations.